Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Disentangling conical intersection and coherent molecular dynamics in methyl bromide with attosecond transient absorption spectroscopy.

Timmers H, Zhu X, Li Z, Kobayashi Y, Sabbar M, Hollstein M, Reduzzi M, Martínez TJ, Neumark DM, Leone SR.

Nat Commun. 2019 Jul 16;10(1):3133. doi: 10.1038/s41467-019-10789-7.

2.

Tpl2 is required for VEGF-A-stimulated signal transduction and endothelial cell function.

Fearnley GW, Abdul-Zani I, Latham AM, Hollstein MC, Ladbury JE, Wheatcroft SB, Odell AF, Ponnambalam S.

Biol Open. 2019 May 17;8(5). pii: bio034215. doi: 10.1242/bio.034215.

3.

Experimental and pan-cancer genome analyses reveal widespread contribution of acrylamide exposure to carcinogenesis in humans.

Zhivagui M, Ng AWT, Ardin M, Churchwell MI, Pandey M, Renard C, Villar S, Cahais V, Robitaille A, Bouaoun L, Heguy A, Guyton KZ, Stampfer MR, McKay J, Hollstein M, Olivier M, Rozen SG, Beland FA, Korenjak M, Zavadil J.

Genome Res. 2019 Apr;29(4):521-531. doi: 10.1101/gr.242453.118. Epub 2019 Mar 7.

4.

Genome-scale mutational signatures of aflatoxin in cells, mice, and human tumors.

Huang MN, Yu W, Teoh WW, Ardin M, Jusakul A, Ng AWT, Boot A, Abedi-Ardekani B, Villar S, Myint SS, Othman R, Poon SL, Heguy A, Olivier M, Hollstein M, Tan P, Teh BT, Sabapathy K, Zavadil J, Rozen SG.

Genome Res. 2017 Sep;27(9):1475-1486. doi: 10.1101/gr.220038.116. Epub 2017 Jul 24.

5.

Modeling cancer driver events in vitro using barrier bypass-clonal expansion assays and massively parallel sequencing.

Huskova H, Ardin M, Weninger A, Vargova K, Barrin S, Villar S, Olivier M, Stopka T, Herceg Z, Hollstein M, Zavadil J, Korenjak M.

Oncogene. 2017 Oct 26;36(43):6041-6048. doi: 10.1038/onc.2017.215. Epub 2017 Jul 10.

6.

Corrigendum: Modelling mutational landscapes of human cancers in vitro.

Olivier M, Weninger A, Ardin M, Huskova H, Castells X, Vallée MP, McKay J, Nedelko T, Muehlbauer KR, Marusawa H, Alexander J, Hazelwood L, Byrnes G, Hollstein M, Zavadil J.

Sci Rep. 2017 Jan 16;7:40898. doi: 10.1038/srep40898. No abstract available.

7.

Nutlin-3a selects for cells harbouring TP53 mutations.

Kucab JE, Hollstein M, Arlt VM, Phillips DH.

Int J Cancer. 2017 Feb 15;140(4):877-887. doi: 10.1002/ijc.30504. Epub 2016 Nov 22.

8.

TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data.

Bouaoun L, Sonkin D, Ardin M, Hollstein M, Byrnes G, Zavadil J, Olivier M.

Hum Mutat. 2016 Sep;37(9):865-76. doi: 10.1002/humu.23035. Epub 2016 Jul 8.

PMID:
27328919
9.

Base changes in tumour DNA have the power to reveal the causes and evolution of cancer.

Hollstein M, Alexandrov LB, Wild CP, Ardin M, Zavadil J.

Oncogene. 2017 Jan 12;36(2):158-167. doi: 10.1038/onc.2016.192. Epub 2016 Jun 6. Review.

10.

An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model.

Jennis M, Kung CP, Basu S, Budina-Kolomets A, Leu JI, Khaku S, Scott JP, Cai KQ, Campbell MR, Porter DK, Wang X, Bell DA, Li X, Garlick DS, Liu Q, Hollstein M, George DL, Murphy ME.

Genes Dev. 2016 Apr 15;30(8):918-30. doi: 10.1101/gad.275891.115. Epub 2016 Mar 31.

11.

The genome as a record of environmental exposure.

Nik-Zainal S, Kucab JE, Morganella S, Glodzik D, Alexandrov LB, Arlt VM, Weninger A, Hollstein M, Stratton MR, Phillips DH.

Mutagenesis. 2015 Nov;30(6):763-70. doi: 10.1093/mutage/gev073. Epub 2015 Oct 6.

12.

Comparison of the metabolic activation of environmental carcinogens in mouse embryonic stem cells and mouse embryonic fibroblasts.

Krais AM, Mühlbauer KR, Kucab JE, Chinbuah H, Cornelius MG, Wei QX, Hollstein M, Phillips DH, Arlt VM, Schmeiser HH.

Toxicol In Vitro. 2015 Feb;29(1):34-43. doi: 10.1016/j.tiv.2014.09.004. Epub 2014 Sep 16.

13.

VEGF-A isoforms differentially regulate ATF-2-dependent VCAM-1 gene expression and endothelial-leukocyte interactions.

Fearnley GW, Odell AF, Latham AM, Mughal NA, Bruns AF, Burgoyne NJ, Homer-Vanniasinkam S, Zachary IC, Hollstein MC, Wheatcroft SB, Ponnambalam S.

Mol Biol Cell. 2014 Aug 15;25(16):2509-21. doi: 10.1091/mbc.E14-05-0962. Epub 2014 Jun 25.

14.

Modelling mutational landscapes of human cancers in vitro.

Olivier M, Weninger A, Ardin M, Huskova H, Castells X, Vallée MP, McKay J, Nedelko T, Muehlbauer KR, Marusawa H, Alexander J, Hazelwood L, Byrnes G, Hollstein M, Zavadil J.

Sci Rep. 2014 Mar 27;4:4482. doi: 10.1038/srep04482. Erratum in: Sci Rep. 2017 Jan 16;7:40898.

15.

A novel p53 mutant found in iatrogenic urothelial cancers is dysfunctional and can be rescued by a second-site global suppressor mutation.

Odell AF, Odell LR, Askham JM, Alogheli H, Ponnambalam S, Hollstein M.

J Biol Chem. 2013 Jun 7;288(23):16704-14. doi: 10.1074/jbc.M112.443168. Epub 2013 Apr 23.

16.

Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid.

Hollstein M, Moriya M, Grollman AP, Olivier M.

Mutat Res. 2013 Jul-Sep;753(1):41-9. doi: 10.1016/j.mrrev.2013.02.003. Epub 2013 Feb 17. Review.

17.

Mammalian cells acquire epigenetic hallmarks of human cancer during immortalization.

Tommasi S, Zheng A, Weninger A, Bates SE, Li XA, Wu X, Hollstein M, Besaratinia A.

Nucleic Acids Res. 2013 Jan 7;41(1):182-95. doi: 10.1093/nar/gks1051. Epub 2012 Nov 11.

18.

Upper urinary tract urothelial cancers: where it is A:T.

Olivier M, Hollstein M, Schmeiser HH, Straif K, Wild CP.

Nat Rev Cancer. 2012 Aug;12(8):503-4. doi: 10.1038/nrc3311.

PMID:
23002458
19.

Evidence of exposure to aristolochic acid in patients with urothelial cancer from a Balkan endemic nephropathy region of Romania.

Schmeiser HH, Kucab JE, Arlt VM, Phillips DH, Hollstein M, Gluhovschi G, Gluhovschi C, Modilca M, Daminescu L, Petrica L, Velciov S.

Environ Mol Mutagen. 2012 Oct;53(8):636-41. doi: 10.1002/em.21732. Epub 2012 Sep 17.

PMID:
22987305
20.

Efficient introduction of specific TP53 mutations into mouse embryonic fibroblasts and embryonic stem cells.

Wei QX, van der Hoeven F, Hollstein M, Odell AF.

Nat Protoc. 2012 May 17;7(6):1145-60. doi: 10.1038/nprot.2012.042.

PMID:
22596227
21.

A VE-cadherin-PAR3-α-catenin complex regulates the Golgi localization and activity of cytosolic phospholipase A(2)α in endothelial cells.

Odell AF, Hollstein M, Ponnambalam S, Walker JH.

Mol Biol Cell. 2012 May;23(9):1783-96. doi: 10.1091/mbc.E11-08-0694. Epub 2012 Mar 7.

22.

Tissue-specific apoptotic effects of the p53 codon 72 polymorphism in a mouse model.

Azzam GA, Frank AK, Hollstein M, Murphy ME.

Cell Cycle. 2011 May 1;10(9):1352-5. Epub 2011 May 1.

23.

Chek2ing out the p53 pathway: can Puma lead the way?

Hollstein M, Hupp T.

Cell Cycle. 2011 May 15;10(10):1524. Epub 2011 May 15. No abstract available.

PMID:
21478674
24.

Rapid derivation of genetically related mutants from embryonic cells harboring a recombinase-specific Trp53 platform.

Wei QX, Odell AF, van der Hoeven F, Hollstein M.

Cell Cycle. 2011 Apr 15;10(8):1261-70. Epub 2011 Apr 15.

PMID:
21445009
25.

The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammation.

Frank AK, Leu JI, Zhou Y, Devarajan K, Nedelko T, Klein-Szanto A, Hollstein M, Murphy ME.

Mol Cell Biol. 2011 Mar;31(6):1201-13. doi: 10.1128/MCB.01136-10. Epub 2011 Jan 18.

26.

Unveiling the methylation status of CpG dinucleotides in the substituted segment of the human p53 knock-in (Hupki) mouse genome.

Kim SI, Hollstein M, Pfeifer GP, Besaratinia A.

Mol Carcinog. 2010 Dec;49(12):999-1006. doi: 10.1002/mc.20683.

27.

How to become immortal: let MEFs count the ways.

Odell A, Askham J, Whibley C, Hollstein M.

Aging (Albany NY). 2010 Mar 31;2(3):160-5. Review.

28.

Gene expression changes induced by the human carcinogen aristolochic acid I in renal and hepatic tissue of mice.

Arlt VM, Zuo J, Trenz K, Roufosse CA, Lord GM, Nortier JL, Schmeiser HH, Hollstein M, Phillips DH.

Int J Cancer. 2011 Jan 1;128(1):21-32. doi: 10.1002/ijc.25324.

29.

TP53 mutations in human cancers: origins, consequences, and clinical use.

Olivier M, Hollstein M, Hainaut P.

Cold Spring Harb Perspect Biol. 2010 Jan;2(1):a001008. doi: 10.1101/cshperspect.a001008. Review.

30.

Wild-type and Hupki (human p53 knock-in) murine embryonic fibroblasts: p53/ARF pathway disruption in spontaneous escape from senescence.

Whibley C, Odell AF, Nedelko T, Balaburski G, Murphy M, Liu Z, Stevens L, Walker JH, Routledge M, Hollstein M.

J Biol Chem. 2010 Apr 9;285(15):11326-35. doi: 10.1074/jbc.M109.064444. Epub 2010 Jan 29.

31.

Massively regulated genes: the example of TP53.

Hollstein M, Hainaut P.

J Pathol. 2010 Jan;220(2):164-73. doi: 10.1002/path.2637. Review.

PMID:
19918835
32.

Increased expression of cell-cell signaling genes by stimulated mononuclear leukocytes in patients with previous atherothrombotic stroke. A whole genome expression profile study.

Grond-Ginsbach C, Horstmann S, Hummel M, Wiest T, Honold C, Pfleger K, Hergenhahn M, Hollstein M, Weninger A, Knyazev Y, Mansmann U, Wagner S, Grau AJ.

Eur Neurol. 2009;62(1):30-9. doi: 10.1159/000215878. Epub 2009 Apr 30.

PMID:
19407453
33.

p53 polymorphisms: cancer implications.

Whibley C, Pharoah PD, Hollstein M.

Nat Rev Cancer. 2009 Feb;9(2):95-107. doi: 10.1038/nrc2584. Review.

PMID:
19165225
34.

TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours.

Nedelko T, Arlt VM, Phillips DH, Hollstein M.

Int J Cancer. 2009 Feb 15;124(4):987-90. doi: 10.1002/ijc.24006.

35.

The carcinogenic air pollutant 3-nitrobenzanthrone induces GC to TA transversion mutations in human p53 sequences.

vom Brocke J, Krais A, Whibley C, Hollstein MC, Schmeiser HH.

Mutagenesis. 2009 Jan;24(1):17-23. doi: 10.1093/mutage/gen049. Epub 2008 Sep 2.

PMID:
18765419
36.

Gene expression in human peripheral blood mononuclear cells upon acute ischemic stroke.

Grond-Ginsbach C, Hummel M, Wiest T, Horstmann S, Pfleger K, Hergenhahn M, Hollstein M, Mansmann U, Grau AJ, Wagner S.

J Neurol. 2008 May;255(5):723-31. doi: 10.1007/s00415-008-0784-z. Epub 2008 May 15.

PMID:
18465111
37.

Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72.

Reinbold M, Luo JL, Nedelko T, Jerchow B, Murphy ME, Whibley C, Wei Q, Hollstein M.

Oncogene. 2008 Apr 24;27(19):2788-94. Epub 2007 Nov 12.

PMID:
17998932
38.

The PEA-15/PED protein protects glioblastoma cells from glucose deprivation-induced apoptosis via the ERK/MAP kinase pathway.

Eckert A, Böck BC, Tagscherer KE, Haas TL, Grund K, Sykora J, Herold-Mende C, Ehemann V, Hollstein M, Chneiweiss H, Wiestler OD, Walczak H, Roth W.

Oncogene. 2008 Feb 14;27(8):1155-66. Epub 2007 Aug 13.

PMID:
17700518
39.

Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer.

Arlt VM, Stiborová M, vom Brocke J, Simões ML, Lord GM, Nortier JL, Hollstein M, Phillips DH, Schmeiser HH.

Carcinogenesis. 2007 Nov;28(11):2253-61. Epub 2007 Apr 13. Review.

PMID:
17434925
40.

p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.

Song H, Hollstein M, Xu Y.

Nat Cell Biol. 2007 May;9(5):573-80. Epub 2007 Apr 8.

PMID:
17417627
41.

Microarray analysis of newly synthesized RNA in cells and animals.

Kenzelmann M, Maertens S, Hergenhahn M, Kueffer S, Hotz-Wagenblatt A, Li L, Wang S, Ittrich C, Lemberger T, Arribas R, Jonnakuty S, Hollstein MC, Schmid W, Gretz N, Gröne HJ, Schütz G.

Proc Natl Acad Sci U S A. 2007 Apr 10;104(15):6164-9. Epub 2007 Apr 3.

42.

An MVA vaccine overcomes tolerance to human p53 in mice and humans.

Song GY, Gibson G, Haq W, Huang EC, Srivasta T, Hollstein M, Daftarian P, Wang Z, Diamond D, Ellenhorn JD.

Cancer Immunol Immunother. 2007 Aug;56(8):1193-205. Epub 2007 Jan 12.

PMID:
17219151
43.

Ser46 phosphorylation regulates p53-dependent apoptosis and replicative senescence.

Feng L, Hollstein M, Xu Y.

Cell Cycle. 2006 Dec;5(23):2812-9. Epub 2006 Dec 1.

PMID:
17172844
44.

Mutagenesis of human p53 tumor suppressor gene sequences in embryonic fibroblasts of genetically-engineered mice.

Liu Z, Belharazem D, Muehlbauer KR, Nedelko T, Knyazev Y, Hollstein M.

Genet Eng (N Y). 2007;28:45-54. No abstract available.

PMID:
17153932
45.

Further studies with a cell immortalization assay to investigate the mutation signature of aristolochic acid in human p53 sequences.

Feldmeyer N, Schmeiser HH, Muehlbauer KR, Belharazem D, Knyazev Y, Nedelko T, Hollstein M.

Mutat Res. 2006 Sep 28;608(2):163-8. Epub 2006 Jul 10.

PMID:
16835015
46.

MEF immortalization to investigate the ins and outs of mutagenesis.

vom Brocke J, Schmeiser HH, Reinbold M, Hollstein M.

Carcinogenesis. 2006 Nov;27(11):2141-7. Epub 2006 Jun 15. Review.

PMID:
16777987
47.

Quantitative analysis of plasma TP53 249Ser-mutated DNA by electrospray ionization mass spectrometry.

Lleonart ME, Kirk GD, Villar S, Lesi OA, Dasgupta A, Goedert JJ, Mendy M, Hollstein MC, Montesano R, Groopman JD, Hainaut P, Friesen MD.

Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2956-62.

48.

Human p53 knock-in (hupki) mice do not differ in liver tumor response from their counterparts with murine p53.

Jaworski M, Hailfinger S, Buchmann A, Hergenhahn M, Hollstein M, Ittrich C, Schwarz M.

Carcinogenesis. 2005 Oct;26(10):1829-34. Epub 2005 May 25.

PMID:
15917304
49.

p53 mutations in benzo(a)pyrene-exposed human p53 knock-in murine fibroblasts correlate with p53 mutations in human lung tumors.

Liu Z, Muehlbauer KR, Schmeiser HH, Hergenhahn M, Belharazem D, Hollstein MC.

Cancer Res. 2005 Apr 1;65(7):2583-7.

50.

Differential effect of imipramine and related compounds on Mg2+ efflux from rat erythrocytes.

Ebel H, Hollstein M, Günther T.

Biochim Biophys Acta. 2004 Dec 15;1667(2):132-40.

Supplemental Content

Loading ...
Support Center